Cara lines up a $440M deal for US rights to its late-stage drug for se­vere itch, with $150M cash on the ta­ble

With plans afoot to file an NDA for what could be its first ap­proved drug, Cara Ther­a­peu­tics is piv­ot­ing its fo­cus to com­mer­cial­iza­tion. And Swiss com­pa­ny Vi­for Phar­ma is will­ing to sur­ren­der up to $440 mil­lion to mar­ket the can­di­date in the US.

Cara $CARA CEO Derek Chalmers said an NDA sub­mis­sion is com­ing this quar­ter for their in­tra­venous drug Ko­r­su­va in chron­ic kid­ney dis­ease-as­so­ci­at­ed pru­ri­tus (CKD-aP), a se­vere itch­ing con­di­tion. The Stam­ford, CT-based biotech read out pos­i­tive topline da­ta from a Phase III piv­otal study back in April, and an­nounced plans to ap­proach EMA reg­u­la­tors short­ly af­ter fil­ing with the FDA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER